Stayble Therapeutics AB (SE:STABL)
:STABL
STABL Stock Chart & Stats
kr0.24
kr0.07(17.59%)
At close: 4:00 PM EST
kr0.24
kr0.07(17.59%)
Day’s Range― - ―
52-Week Rangekr0.15 - kr0.63
Previous CloseN/A
Volume514.07K
Average Volume (3M)378.51K
Market Cap
kr11.17M
Enterprise Valuekr8.72M
Total Cash (Recent Filing)kr2.45M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,359,795
10 Day Avg. Volume398,578
30 Day Avg. Volume378,512
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.92
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Loss & Cash Burn TrendThe company has materially reduced operating losses and cash burn over several years, showing sustained cost control and operational tightening. This durable improvement lengthens runway, lowers near-term financing need probability, and improves the odds of reaching clinical milestones before next funding.
Low LeverageA near-zero debt position keeps fixed obligations minimal and preserves financial flexibility—critical for a development-stage biotech. Low leverage reduces interest burden and bankruptcy risk, making future capital structure choices simpler and supporting long-term R&D execution.
Focused Lead Asset With Differentiated ApproachA single, focused lead program pursuing disease-modifying treatment for degenerative disc disease provides strategic clarity and potential clinical differentiation. A mechanistic, pathology-targeting asset can command higher clinical value and create durable competitive advantage if trials succeed.
Bears Say
No RevenueBeing pre-revenue means the business model has not yet demonstrated commercial viability; the company depends entirely on external financing until product approval and sales. This structural revenue absence makes long-term funding and valuation outcomes highly dependent on clinical success and capital markets.
Shrinking Equity BaseMarked erosion of equity and assets reflects cumulative losses and likely dilution, weakening the balance sheet cushion. A compressed equity base reduces the company's ability to absorb setbacks, increases likelihood of future dilutive raises, and raises execution risk for long-term development plans.
Persistent Negative Operating Cash FlowConsistent negative operating cash flow forces reliance on external capital to fund R&D and operations. Even with an improving burn, the absence of internal cash generation creates structural liquidity risk: capital raises may be required at inopportune times, diluting shareholders and constraining long-term strategy.
STABL FAQ
What was Stayble Therapeutics AB’s price range in the past 12 months?
Stayble Therapeutics AB lowest stock price was kr0.15 and its highest was kr0.63 in the past 12 months.
What is Stayble Therapeutics AB’s market cap?
Stayble Therapeutics AB’s market cap is kr11.17M.
When is Stayble Therapeutics AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Stayble Therapeutics AB’s earnings last quarter?
Currently, no data Available
Is Stayble Therapeutics AB overvalued?
According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued.
Does Stayble Therapeutics AB pay dividends?
Stayble Therapeutics AB does not currently pay dividends.
What is Stayble Therapeutics AB’s EPS estimate?
Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stayble Therapeutics AB have?
Stayble Therapeutics AB has 64,359,795 shares outstanding.
What happened to Stayble Therapeutics AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Stayble Therapeutics AB?
Currently, no hedge funds are holding shares in SE:STABL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Stayble Therapeutics AB
Stayble Therapeutics AB (STABL) is a clinical-stage pharmaceutical company based in Sweden that focuses on developing innovative treatments for degenerative disc disease and other musculoskeletal disorders. The company is primarily engaged in the research and development of non-surgical therapies that address the underlying causes of chronic back pain, offering potential relief and improved quality of life for patients.